We caught up with the European Association for the Study of the Liver (EASL) Vice-Secretary, Prof. Aleksander Krag, to discuss the upcoming International Liver Congress (ILC) and what to expect. At ILC 2022 they will be bringing back face-to-face meetings in a new model, reshaping the scientific programme, offering a fresh experience, merging the very best of ILC tradition and cutting-edge developments. The event will continue to maintain an online presence, providing opportunities for virtual access to the educational content.
- Could you give us a brief overview of the European Association for the Study (EASL), its objectives, and strategic directions?
- Could you tell us a little about the upcoming International Liver Congress?
- What research topics can attendees expect at the upcoming congress?
- Could you give us an overview of the press releases and news coverage to expect?
Access the Scientific Programme here: www.easl.eu/event/international-liver-congress-2022/scientific-programme/
EASL, the European Association for the Study of the Liver, founded in 1966, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology. As of 2021, EASL serves more than 4,200 members. EASL engages globally with all stakeholders in the field of hepatology, worldwide. Their aim is to spread knowledge and expertise in best practices and the latest scientific breakthroughs in this field. They advocate for the benefit of patients and advise European and national health authorities. EASL runs topical conferences, schools, and related educational meetings.
Disclosures: Aleksander Krag has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
View more EASL content here
Share this Video
Related Videos In Liver Disorders
Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – clinical endpoints and next steps
CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. We caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the primary and secondary endpoints and how well they were achieved, and the […]
Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – aims and design
CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. In this touchENDOCRINOLOGY interview, we caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the mechanism of action of CM-101, and the aims, […]
Paul Brennan: International NASH day 2023
International NASH Day (NASH Day) takes place on the 8th June 2023. It is a public education campaign launched in June 2018 to raise visibility and urgency around fatty liver disease and its more advanced form, nonalcoholic steatohepatitis (NASH), which affects more than 115 million people around the world. We were delighted to talk with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!